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Reply to: Prospective MRI-score to predict negative EULAR-response in patients with 
rheumatoid arthritis (RA) before therapy-escalation to a biological therapy.  
Sewerin P, Vordenbaeumen S, Brinks R, Ostendorf B. 
 
Dear Editor and authors,  
We thank Sewerin et al for the data they have provided on the predictive role of 
Magnetic Resonance Imaging (MRI) for clinical response in rheumatoid arthritis (RA).[1] 
This study follows on from our previous study demonstrating the predictive value of MRI 
for radiographic damage progression.[2] This study by Sewerin builds on the evidence 
for MRI as a imaging biomarker by demonstrating a prediction of clinical response. The 
investigators used the German REMISSION-PLUS [3] cohort and studied 29 patients 
who were being escalated to biologic therapy due to inadequate disease control. Clinical 
EULAR response to the biologic was more likely in those with higher RA MRI (RAMRIS) 
scores prior to the escalation of therapy. While these study results need to be replicated 
in a larger cohort, this study provides initial evidence that MRI measures can help predict 
who is most likely to benefit from more aggressive interventions.  
 
The concept that MRI more accurately identifies clinically relevant synovitis than clinical 
assessment is well-established.[4] One hypothesis for why MRI might be a useful 
predictive biomarker for therapeutic response is that some patients with apparently 
active RA have elevated disease activity measures due to comorbid conditions, rather 
than active joint inflammation. For example, a recent study showed that obese patients 
are less likely to reach clinical remission.[5] Those with elevated disease activity 
measures without objective evidence of inflammatory disease would be very unlikely to 
improve with more aggressive treatment of the RA. In contrast, those with greater MRI-
detected activity might be expected to have a greater proportion of their clinical disease 
activity explained by active RA.  
 
Limitations of this study are the small sample size and lack of a more detailed 
characterization of the study population. However, this study begins to answer an 
important question in RA, namely - can MRI help rheumatologists make more accurate 
decisions about escalation of therapy? Given that escalation to biologic therapy involves 
increased risk of side effects and cost, biomarkers that define both cases at greatest risk 
of joint destruction and those most likely to benefit clinically are of major interest. MRI, 
despite being expensive, is likely to be cost-effective in circumstances when its use 
prevents unnecessary or inappropriate use of much more expensive and long-term 
therapies. 
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